FDA fast-track designation goes to Alkermes' depression candidate

10/11/2013 | American City Business Journals · Bloomberg Businessweek

The FDA has given its fast-track designation to Alkermes' ALKS 5461, an experimental drug for major depressive disorder intended to help patients when other treatments don't provide relief. Alkermes plans to initiate a late-stage trial in early 2014.

View Full Article in:

American City Business Journals · Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC